Jun. 12 at 3:52 AM
$LUNG https://www.investing.com/news/transcripts/pulmonx-at-goldman-sachs-conference-strategic-growth-insights-93CH-4091529
Pulmonx at Goldman Sachs Conference: Strategic Growth Insights
Wednesday, the 11th of June 2025, Pulmonx Corp (NASDAQ:LUNG) presented its strategic vision at the Goldman Sachs 46th Annual Global Healthcare Conference. The company outlined its market position, financial performance, and future growth strategies, highlighting both opportunities and challenges in the evolving healthcare landscape.
-Pulmonx targets a
$12 billion total addressable market for severe emphysema.
-The company reported 22% revenue growth last year, with a strong cash position of
$88.7 million.
-Zephyr valve technology is central to Pulmonx's strategy, backed by strong clinical validation.
-Geographic expansion plans include China and Japan, with significant market potential.
The "acquire, test, and treat" strategy aims to bridge the gap between patient activation and procedures performed.
